Skip to main content

Search Videos and More

Showing 97 - 108 of 162 results

Previous| 1... 8 | 9 | 10 ...14 |Next

From a lipid medicine specialist’s perspective, what would your approach be to a post-ACS patient with two stents and triple-vessel disease whose LDL-C level is 70 mg/dL?

From a lipid medicine specialist’s perspective, what would your approach be to a post-ACS patient with two stents and triple-vessel disease whose LDL-C level is 70 mg/dL?

How do you view the lack of current safety signals encountered in CV outcome trials with PCSK9 inhibitors? What are the implications for lifelong use of these agents?

How do you view the lack of current safety signals encountered in CV outcome trials with PCSK9 inhibitors? What are the implications for lifelong use of these agents?

From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?

As an IC, you are seeing post-ACS/post-PCI patients whose atherosclerotic disease burden is exceptional and potentially amenable to PCSK9-mediated CV risk reduction. Where is your specific focus for using these agents in this population?

How do you interpret the reduction in associated overall mortality seen with alirocumab in the ODYSSEY Outcome Trial as compared to the lack of such findings—at least prior to results for the extension phase in FOURIER —for the evolocumab trial?

How do you interpret the reduction in associated overall mortality seen with alirocumab in the ODYSSEY Outcome Trial as compared to the lack of such findings—at least prior to results for the extension phase in FOURIER —for the evolocumab trial?

Considering that younger persons are vulnerable to carrying a lifelong atherosclerosis burden when their LDL-C levels are elevated, how to do approach them management-wise?

Considering that younger persons are vulnerable to carrying a lifelong atherosclerosis burden when their LDL-C levels are elevated, how to do approach them management-wise?

How have the 2016 Canadian Cardiovascular Society Guidelines for LDL-C reduction positioned their recommendations for LDL-C target goals, and how do you anticipate these might change in the future based on the ODYSSEY Outcomes and FOURIER Trials?

How have the 2016 Canadian Cardiovascular Society Guidelines for LDL-C reduction positioned their recommendations for LDL-C target goals, and how do you anticipate these might change in the future based on the ODYSSEY Outcomes and FOURIER Trials?

Given the new AHA Guidelines and the anticipation of new ESC Guidelines in 2019, what is your view about LDL-C level target thresholds vs. degree of LDL-C reduction? What level do you consider optimal in high-risk patients with progressive ASCVD?

Given the new AHA Guidelines and the anticipation of new ESC Guidelines in 2019, what is your view about LDL-C level target thresholds vs. degree of LDL-C reduction? What level do you consider optimal in high-risk patients with progressive ASCVD?

ODYSSEY Outcomes reports that post-ACS patients with starting LDL-C levels greater than 100 mg/dL benefited most, but you have noted the importance of assessing “aggregate risk” when identifying triggers for PCSK9-based therapy. Can you discuss this?

ODYSSEY Outcomes reports that post-ACS patients with starting LDL-C levels greater than 100 mg/dL benefited most, but you have noted the importance of assessing “aggregate risk” when identifying triggers for PCSK9-based therapy. Can you discuss this?

Which patients, in your view, based on the ODYSSEY Outcomes and FOURIER trials, do you want to drive below the LDL-C “threshold” of 70 mg/dL? What is your rationale and how do you select your patients and achieve your targets in the real world?

Which patients, in your view, based on the ODYSSEY Outcomes and FOURIER trials, do you want to drive below the LDL-C “threshold” of 70 mg/dL? What is your rationale and how do you select your patients and achieve your targets in the real world?

What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab?

What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab?

Should lipidologists consider other markers such as apoB as well as LDL-C for reducing CV risk in diabetes and hypertriglyceridemia?

Should lipidologists consider other markers such as apoB as well as LDL-C for reducing CV risk in diabetes and hypertriglyceridemia?

Showing 97 - 108 of 162 results

Previous| 1... 8 | 9 | 10 ...14 |Next